Get started
Author

Karen Kelly

Adjuvant erlotinib versus observation after complete resection of EGFR -mutant NSCLC: Final overall survival results of Alliance A081105.
2026 · Ramaswamy Govindan, Sumithra J. Mandrekar, et al. · Journal of Clinical Oncology · 2
Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial
2026 · Megan E Daly, Charles B Simone, et al. · The Lancet · 1
The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancer
2026 · Shetal A. Patel, Jonathan L. Heald, et al. · Cancer · 1
A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer
2026 · Charles X. Wang, Guillaume Luxardi, et al. · OncoImmunology
PDF
Immune-related adverse event severity and clinical outcomes with immune checkpoint inhibitor immunotherapy in participants with non–small cell lung cancer: Analysis of the lung MAP sub-studies S1400A, S1400I, S1400F, and S1800A.
2026 · Diane Tseng, James Moon, et al. · Journal of Clinical Oncology
A randomized phase II study of capmatinib plus osimertinib with or without ramucirumab in patients with EGFR -mutant, MET -amplified stage IV or recurrent no–small cell lung cancer (Lung-MAP Sub-Study S1900G).
2026 · Sarah B. Goldberg, Mary Weber Redman, et al. · Journal of Clinical Oncology
PDF
Works count: 6
Citation count: 4
H-index: 1
I10-index:
Year
Topic
Type